Table 1.
Characteristic | n (%) |
---|---|
Age in years | |
<40 | 25 (31.6) |
40–60 | 46 (58.2) |
>60 | 8 (10.1) |
Median (range) | 46 (19–74) |
Menstrual status | |
Premenopausal | 52 (65.8) |
Menopausal | 27 (34.2) |
Family history of breast cancer | |
Yes | 5 (6.3) |
No | 66 (83.5) |
Unknown | 8 (10.1) |
Affected side | |
Left | 38 (48.1) |
Right | 41 (51.9) |
Clinical tumour size | |
Tx | 1 (1.3) |
T1 | 6 (7.6) |
T2 | 33 (41.8) |
T3 | 23 (29.1) |
T4 | 15 (19) |
Inflammatory breast cancer | 1 (1.3) |
Clinical node status | |
N0 | 41 (51.9) |
N1 | 26 (32.9) |
N2 | 11 (13.9) |
N3 | 1 (1.3) |
Clinical stage at presentation | |
I | 5 (6.3) |
II | 41 (51.9) |
III | 33 (41.8) |
Tx = tumour size could not be ascertained; T1 = tumour of ≤2 cm; T2 = tumour of 2.1–5 cm; T3 = tumour of >5 cm; T4 = tumour of any size invading the chest wall, breast skin (ulceration or macroscopic nodules) or inflammatory carcinoma; N0 = absence of nodal involvement; N1 = metastasis to the ipsilateral axillary lymph nodes that are mobile; N2 = metastasis to the ipsilateral axillary lymph nodes that are fixed; N3 = metastasis to the ipsilateral infra-clavicular lymph nodes with or without axillary lymph nodes.